Saniona AB, a pharmaceutical company based in Denmark, focuses on developing drugs for central nervous system diseases, autoimmune diseases, metabolic diseases, and pain management. Specializing in ESG research, the company leverages a technology platform to explore various ion channel drug targets including GABAA receptors, nicotinic acetylcholine receptors, and potassium channels. With a high risk assessment and an ESG score of 36.1, Saniona AB's product pipeline includes Tesomet, SAN711, Tesofensine, SAN903, and SAN2219.